ADMA Biologics, Inc. (NASDAQ:ADMA) Given Consensus Rating of “Buy” by Brokerages

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) have been assigned a consensus rating of “Buy” from the four analysts that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.00.

Several analysts have recently commented on the stock. Raymond James increased their price target on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a research report on Thursday, August 10th. TheStreet raised ADMA Biologics from a “d” rating to a “c-” rating in a research report on Friday, May 19th. StockNews.com upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright increased their price objective on ADMA Biologics from $4.50 to $5.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, Cantor Fitzgerald upped their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Thursday, August 10th.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 130,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $3.71 per share, for a total transaction of $482,300.00. Following the acquisition, the director now directly owns 443,265 shares in the company, valued at $1,644,513.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other ADMA Biologics news, Director Jerrold B. Grossman bought 130,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was purchased at an average price of $3.71 per share, with a total value of $482,300.00. Following the transaction, the director now owns 443,265 shares in the company, valued at $1,644,513.15. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Young Kwon bought 25,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $3.90 per share, for a total transaction of $97,500.00. Following the purchase, the director now owns 277,401 shares in the company, valued at approximately $1,081,863.90. The disclosure for this purchase can be found here. Over the last three months, insiders sold 2,405,351 shares of company stock worth $9,875,175. 6.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Pictet Asset Management SA lifted its position in ADMA Biologics by 46.4% during the 1st quarter. Pictet Asset Management SA now owns 32,474 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 10,295 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of ADMA Biologics in the fourth quarter valued at $653,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of ADMA Biologics by 391.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 814,836 shares of the biotechnology company’s stock valued at $3,162,000 after purchasing an additional 649,198 shares during the period. Inspire Investing LLC acquired a new stake in ADMA Biologics during the 1st quarter valued at $540,000. Finally, EWG Elevate Inc. purchased a new stake in ADMA Biologics during the 1st quarter worth $331,000. Hedge funds and other institutional investors own 73.58% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $3.89 on Monday. The business has a 50 day moving average price of $3.90 and a 200 day moving average price of $3.69. The company has a market capitalization of $874.88 million, a P/E ratio of -19.45 and a beta of 0.79. ADMA Biologics has a 1-year low of $2.24 and a 1-year high of $4.65. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.35 and a quick ratio of 2.49.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). ADMA Biologics had a negative return on equity of 27.55% and a negative net margin of 19.36%. The business had revenue of $60.12 million during the quarter, compared to analysts’ expectations of $55.45 million. During the same quarter last year, the business posted ($0.07) earnings per share. Sell-side analysts expect that ADMA Biologics will post -0.06 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.